Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sirolimus Dose Requirement in Kidney Transplant Recipients in Iran Pubmed



Ghasemi G1 ; Shahidi S1 ; Farajzadegan Z2 ; Shahidi S1 ; Mohammadi M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Community Medicine Department, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Health Vice Chancellery, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Khorshid Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Iranian Journal of Kidney Diseases Published:2020


Abstract

Introduction. Sirolimus (Rapamune) is an important immunosuppressive drug in kidney transplant patients. The usual maintenance dose of Sirolimus in these patients is 2 to 5 mg/d and its optimal maintenance trough level is 5 to 10 ng/mL. The required Sirolimus doses may differ markedly from patient to patient. It is because of high inter and intrapatient variability in its pharmacokinetics. There have been no studies in Iran on the correlation of Sirolimus blood level and its target dose. This study has been done to show the target dose of Sirolimus in kidney transplanted patients in Isfahan. Methods. This is a longitudinal cross-sectional study conducted from June 2018 to September 2019. The study population included all kidney transplanted patients treated with Sirolimus in a nephrology private clinic. Inclusion criteria were age (equal or more than 18 years old) and the existence of complete data in the patient’s file. The participants were excluded if there were not at least two Sirolimus levels in the patient’s file. Demographics and other variables were extracted from the patient’s files. Results. Sirolimus was prescribed for seventy-three patients. Sixteen patients did not have the inclusion criteria. Fifty-seven renal transplanted patients were included in the study. The mean starting dose of Sirolimus in these patients was 2 ± 0.19 mg/d. The mean of the Sirolimus dose was 1.2 ± 0.44 mg/d. There was more than 20% GFR improvement in 68% of the patients after changing the Calcineurin Inhibitor to Sirolimus (P < .05). Conclusion. In a significant number of patients changing CNI to Sirolimus accompanied by GFR improvement. Contrary to the recommended dose of Sirolimus in the references (2 to 5 mg/d) Iranian kidney transplant recipients needed lower daily doses of Sirolimus (1.2 mg/d) to achieve the desired whole blood level. Further studies are recommended to confirm it. © 2020, Iranian Society of Nephrology. All rights reserved.
Related Docs
View other Related Docs
1. The Side Effect Profile of Sirolimus and Its Relationship With Some Variables: A Retrospective Study of Iranian Renal Transplant Patients, Journal of Research in Medical Sciences (2023)
2. Sirolimus-Induced Pulmonary Toxicity Without Recurrence More Than 8 Years After Everolimus Replacement in a Renal Transplant Patient With Recurrent Skin Scc: A Case Report, BMC Nephrology (2024)
3. The Investigation of Total Anti-Oxidant Capacity and Its Correlation With Immunosuppressive Drug Blood Levels After Kidney Transplantation, Urologiia (Moscow, Russia : 1999) (2024)
4. Survival of Post-Transplant Lymphoproliferative Disorder After Kidney Transplantation in Patients Under Rapamycin Treatment, International Journal of Hematology-Oncology and Stem Cell Research (2021)
5. Predictive Values of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio for Systemic Inflammatory Response Syndrome After Percutaneous Nephrolithotomy, Translational Research in Urology (2021)
6. Modelling Tacrolimus Auc in Acute and Chronic Liver Disease Immediately After Transplant, Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft (2004)
7. The Effect of Ezetimibe on Lipid Profile and Renal Function and Its Side Effects in Renal Transplant Recipients, Journal of Isfahan Medical School (2011)
8. Pharmacokinetics of Tacrolimus Immediately After Liver Transplantation, Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft (2004)
Experts (# of related papers)
View all Related Experts
Shahrzad Shahidi (6)
Zahra Tolou-Ghamari (4)
Other Related Docs
9. 8-Year Survival Analysis of Kidney Transplantation and Determining the Factors Affecting It in Kidney-Transplanted Patients in Noor Hospital in Isfahan, Iran, Journal of Isfahan Medical School (2017)
10. Laboratory Monitoring of Cyclosporine Pre-Dose Concentration (C 0) After Kidney Transplantation in Isfahan, Iranian Journal of Medical Sciences (2003)
11. Preliminary Study of Kidney Transplantation From 2007-2019 in Isfahan, Iran, New Emirates Medical Journal (2024)
12. Evaluation of Magnesium Level and Associated Factors in Patients Under Peritoneal Dialysis, Journal of Isfahan Medical School (2020)
13. One-Year Multicenter Double-Blind Randomized Clinical Trial on the Efficacy and Safety of Generic Cyclosporine (Iminoral) in De Novo Kidney Transplant Recipients, Experimental and Clinical Transplantation (2015)